Market closed
Mersana Therapeutics/$MRSN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mersana Therapeutics
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Ticker
$MRSN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
102
ISIN
US59045L1061
Website
MRSN Metrics
BasicAdvanced
$40M
-
-$0.56
1.65
-
Price and volume
Market cap
$40M
Beta
1.65
52-week high
$2.88
52-week low
$0.26
Average daily volume
2.6M
Financial strength
Current ratio
2.192
Quick ratio
2.155
Long term debt to equity
-128.825
Total debt to equity
-301.315
Interest coverage (TTM)
-18.93%
Management effectiveness
Return on assets (TTM)
-24.73%
Return on equity (TTM)
-505.14%
Valuation
Price to revenue (TTM)
0.965
Price to book
-3.88
Price to tangible book (TTM)
-3.88
Price to free cash flow (TTM)
-0.474
Growth
Revenue change (TTM)
9.88%
Earnings per share change (TTM)
-61.81%
3-year revenue growth (CAGR)
880.21%
3-year earnings per share growth (CAGR)
-38.35%
What the Analysts think about MRSN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mersana Therapeutics stock.
MRSN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MRSN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MRSN News
AllArticlesVideos
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
GlobeNewsWire·2 weeks ago
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mersana Therapeutics stock?
Mersana Therapeutics (MRSN) has a market cap of $40M as of May 10, 2025.
What is the P/E ratio for Mersana Therapeutics stock?
The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of May 10, 2025.
Does Mersana Therapeutics stock pay dividends?
No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Mersana Therapeutics dividend payment date?
Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.
What is the beta indicator for Mersana Therapeutics?
Mersana Therapeutics (MRSN) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.